POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY

被引：0
|
作者：
Matasar, M. [1 ]
Herrera, A. F. [2 ]
Kamdar, M. [3 ]
Mehta, A. [4 ]
Assouline, S. [5 ]
Fleury, I. [6 ,7 ]
Kim, T. M. [8 ]
Kim, W. S. [9 ]
Bosch, F. [10 ]
Radford, J. [11 ,12 ]
Flowers, C. R. [13 ]
Bu, L. [14 ]
Hong, W. -J. [15 ]
Sehn, L. H. [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Colorado, Denver, CO 80202 USA
[4] Univ Birmingham, Dept Med, Birmingham, W Midlands, England
[5] Jewish Gen Hosp, Montreal, PQ, Canada
[6] Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ, Canada
[7] Univ Montreal, Montreal, PQ, Canada
[8] Seoul Natl Univ Hosp, Seoul, South Korea
[9] Samsung Med Ctr, Seoul, South Korea
[10] Hosp Univ Vall dHebron, Barcelona, Spain
[11] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[12] Christie NHS Fdn Trust, Manchester, Lancs, England
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Roche, Shanghai, Peoples R China
[15] Genentech Inc, San Francisco, CA 94080 USA
[16] BC Canc Agcy, Vancouver, BC, Canada
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S468
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [21] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hirata, Jamie
    Perretti, Thomas
    Musick, Lisa
    McMillan, Andrew K.
    [J]. BLOOD, 2021, 138
  • [23] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
    Herrera, Alex F.
    Matasar, Matthew J.
    Assouline, Sarit
    Kamdar, Manali
    Mehta, Amitkumar
    Fleury, Isabelle
    Kim, Won Seog
    Kim, Tae Min
    Bosch, Francesc
    Radford, John A.
    Bu, Lilian
    Hong, Wan-Jen
    Sehn, Laurie H.
    [J]. BLOOD, 2016, 128 (22)
  • [24] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (03) : 201 - 204
  • [25] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, : 201 - 204
  • [26] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [27] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    [J]. Annals of Hematology, 2022, 101 : 979 - 989
  • [28] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    [J]. ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [29] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
    Gritti, Giuseppe
    Marlton, Paula
    Phillips, Tycel J.
    Arthur, Christopher
    Bannerji, Rajat
    Corradini, Paolo
    Johnston, Anna
    Seymour, John F.
    Yuen, Sam
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Flowers, Christopher
    [J]. BLOOD, 2020, 136
  • [30] Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma
    Shinmura, Kohei
    Okubo, So
    Kadota, Saori
    Nakayama, Hitomi
    Sakurai, Aki
    Kurosawa, Shuhei
    Ito, Chisako
    Aisa, Yoshinobu
    Nakazato, Tomonori
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (01) : 223 - 225
12345